Phase 2 study of regorafenib in patients with progressive glioblastoma after failure of bevacizumab
Clicks: 3
ID: 316923
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
0.6
/100
3 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #84 of 105 articles by views in Neuro-Oncology Advances
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Treatment options in progressive glioblastoma (GBM) are limited, especially in patients who have experienced disease progression while receiving bevacizumab therapy. This phase 2 study was conducted to evaluate the efficacy and safety of regorafenib monotherapy in patients with GBM. Methods Eligible patients had radiographic progression of histologically confirmed GBM following second- or third-line bevacizumab therapy. They received regorafenib monotherapy using the dose escalation strategy demonstrated in the ReDOS phase 2 clinical trial evaluating regorafenib in metastatic colon cancer. The target dose was 160 mg once daily, administered for 3 weeks on/1 week off in 28-day cycles. Patients underwent brain magnetic resonance imaging (MRI) every 8 weeks and were assessed via modified Response Assessment in Neuro-Oncology (RANO) criteria. Patients continued treatment with regorafenib therapy until they experienced progression or excessive toxicity. Results Based on the analysis of 13 enrolled patients, there were no responses and 12 of 13 (92.3%) had progressive disease (PD) on brain MRI; 1 patient went off study due to an adverse event (AE) occurring before assessment. The median OS was 4.1 months (95% CI 2.0—7.3). The OS at 12 months was 23% (0.2—46). The PFS at both 3 and 6 months was 7.7% (0.0—22.2%) with a median PFS of 1.0 month, (0.4—1.8). There was a total of 14 Grade 3 or 4 adverse events and no Grade 5 adverse events. Conclusions Regorafenib did not improve OS or PFS in bevacizumab-refractory recurrent glioblastoma. The study was halted early due to futility. Trial Registration NCT04051606
| Reference Key |
openalex_W7164146807
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Alyssa Lucas, David M. Peereboom, Yasmeen Rauf, Hong Li, J. Hanlon, Manmeet S. Ahluwalia |
| Journal | Neuro-Oncology Advances |
| Year | 2026 |
| DOI |
10.1093/noajnl/vdag144
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.